Genedx Holdings Corp. · NASDAQ:WGS
Genedx — Sema4 Holdings — Investor Presentation (March 2022)
25 slides from Genedx's investor presentation, Mar 15, 2022
Slide 1: Sema4 Investor Presentation March 2022
sema4 Investor Presentation March 2022
Slide 2: Disclaimer
Disclaimer ‘This presentation contsins forwatooking statements under the mearing ofthe Private Secures Liigaton Reform Actof 1985. Foruaréooking statements ae statements that do not late to historical facts and events and uch statements and opinions pertaining to the future that, fo beampls. contain
Slide 3: A Patient-Centered Health Intelligence Company
A Patient-Centered Health Intelligence Company Leveraging Genomics and Al
Slide 4: Corporate Snapshot
Corporate Snapshot World-classteam 2022 guidance Unrivaledpatientaccess Massivescaleindata Massivescalein NGS 1,200+ employees $215-225M Semad 12M de-identified records 46+ petabytes 250,000+° 460+MDs/PhD’s' standalone revenue2 500k+w/ genomic profiles managed growing at an tests annually 300k+ clin
Slide 5: Sema4 & GeneDx Combination Drives Growth & Profitability
Sema4 & GeneDx Combination Drives Growth & Profitability Standalone Revenue (Historical and Estimated, $ millions) Pro Forma (ex-COVID, $ millions) Long-Term Growth 2020A 20216 2022E 2023E 20246 2025E Revenue Growth? +20% +21% +36% +34% = +28% Adjusted Gross Margin 5% 16% 33% 43% 50% Proforma FCF#($
Slide 6: The Problem
The Problem Rapid advances in Genomics & Al... ...but limited impact on patients Microbiome Cost Information Diagnoses Device Acquired sema4
Slide 7: Our Solution: A Holistic Approach to Patient Care...
Our Solution: A Holistic Approach to Patient Care... technologies, each with re Use of multiple methods and accuracy of >99% science and methodologies Continuous investment in R&D to identify insights that advance reproductive health risk modeling Contracted with all major national payors Affordable
Slide 8: ...Combined with Centrellis, our Flywheel for Patient Data and Insights
...Combined with Centrellis, our Flywheel for Patient Data and Insights Enhanced Data Feed Channels Insights & Engagement Health Systems Clinical Trials EMR, Imaging, Molecular, Claims Clinical Decision Support Third Parties EMR, Imaging, Molecular, Claims Population Health Models Patients & Provide
Slide 9: Deep Partnership with Health Systems
Deep Partnership with Health Systems (Accelerating clinical exome with GeneDx) Conventional Genomics Model narrow menu Enabling Precision Medicine sold altect toon as the Standard of Care no (or limited) data integration no or limited patient engagement sema4
Slide 10: Evolution Towards a Platform of Algorithms
Evolution Towards a Platform of Algorithms io: Increased Value to Patients, Providers. MONETIZE INFORMATION PLATFORM TO QUERY FOR INSIGHTS Matching patients to Pharma products and services (moving beyond providers and life science) SECONDARY INSIGHTS Novel disease models that inform clinical care an
Slide 11: The Value of Data: Must be Longitudinal and Prescriptive
The Value of Data: Must be Longitudinal and Prescriptive dlected aver me —_—_—_——— semea Collected over time + Curated disease specific ENRICHED EE ference’ ao One LLL fon Collected over time + Curated cinicalnotes ET 6) 6202" 8 CO ey z / g —“(t;Cis ; LONGITUDINAL gE “: SOPHIA GENETICS Collected ove
Slide 12: Traction with Health Systems Remains Robust
Traction with Health Systems Remains Robust Founder Health + Held 1st Founder Health System Consortium + Network is building a combined point of view that will help the industry understand the System power of shared data Consortium + Meetings will be held quarterly * Continuing to scale population h
Slide 13: Enabling Biopharma Partners and Customers
Enabling Biopharma Partners and Customers — SEMA4 OFFERING Deep Partnerships leveraging data science Clinical trial matching SaaS-based licensing ;— LEADIDENTIFICATION —4 ;—— EARLY CLINICAL ———) PROTOCOL OPTIMIZATION REAL WORLD DATA. Drive increased probability of Reduce trial duration, Maximize tri
Slide 14: Enhancing Our Reach into Health Systems & Biopharma
Enhancing Our Reach into Health Systems & Biopharma Molecular Profiling and Real-World Evidence Merus Patient ID and Recruitment SANOFI Drug Discovery Collaboration — janssen J Clinical Trial Match and Recruitment into Trials wiHealth System Partners Lilt, Precision Medicine Drug Screening Collabora
Slide 15: A Market-Leading AI-Driven Genomic & Clinical Data Platform
A Market-Leading Al-Driven Genomic & Clinical Data Platform = Semad4: 288K tests/year, 500K+ genomic profiles Generating Data/ Growing Patient Base * GeneDx: 145K tests/year, 300K+ clinical exomes with 180K+ patient-child trios for deeper insights More holi patient engagement > bigger data Increasin
Slide 16: Broad Portfolio Increases Longitudinal Engagement and Enhances Centrellis
Broad Portfolio Increases Longitudinal Engagement and Enhances Centrellis® ' ' ' ' ' ' \ ' ' ' ' ' ' \ Women’s > NICU & Newborn \ \ ' ' ' ' ' ' \ ' \ ' ' ' L Genomic Health =o : 5 ncology: $18B Health: $4B Outpatient: $3B | | Screening: $10B | Screening: $16B gy: § tot ' ' Reimbursement expanding Su
Slide 17: Strong Close to FY2021
Strong Close to FY2021 17 4Q Resulted Volume + 4Q21 Revenue excluding COVID-19 was $47.3 million 4Q Total Revenue Generated $58 million of revenue 24% growth YoY excluding COVID-19 revenue’ 4Q Balance Sheet $401 million in Cash & Cash Equivalents as of 12/31/21 sems4
Slide 18: Operational Improvements: Key Highlights and Future Focus
Operational Improvements: Key Highlights and Future Focus Lab Operations Key Actions = Hired seasoned SVP Lab Operations = Key investments in Lab Automation Areas of Focus in 2022 = Improve turn-around-times = Portfolio optimization 18 Commercial Reach Key Actions = Increased salesforce headcount by
Slide 19: Creating the Leading Genomic Data Platform, from Generation to Insights
Creating the Leading Genomic Data Platform, from Generation to Insights C1) Serving Patients Throughout Life, Deeply Integrated Within Health Systems e Driving Growth and Scale in Genomic Diagnostics sema4 + © Complementary Revenue Streams and Margin Optimization Opportunity Genek Strengthening Mark
Slide 20: Slide 20
Slide 21: Appendix
Slide 22: Historical COVID Revenue Mix
Historical COVID Revenue Mix % of Total Revenue’ 1Q20 2Q20 3Q20 FY20 1021 2Q21 3Q21 4Q21 ae 99% 93% 84% 79% 73% 87% 86% 79% COVID 0% 6% 14% 18% 25% 8% 10% 18% Other 1% 1% 2% 2% 2% 4% 4% 3% 22 * Certainperiods donotadato 100% aueto rouncing sema4
Slide 23: Non-GAAP Gross Margin Reconciliation
Non-GAAP Gross Margin Reconciliation USD in thousands FY2020 (Restated) FY2021 (Restated) 1a 20 30 40. iad 10 20 30 40. ia Revenue 46,655 30,102 38,608 63957 179,322 64201 7015 43,178 57,801 212,195 cost of Service 37,138 34,505 34,022 63631 175,296 68524 48,179 51,487 60,607 228,797 [Gross (Loss) P
Slide 24: Non-GAAP EBITDA Reconciliation
Non-GAAP EBITDA Reconciliation USD in thousands Fy2020 (Restated) Fy2021 (Restated?) 1a 20 30 4a, FY 10 20 3a 40, Fy Net Profit (Less) (25,980) (22,052) (66,615) (225,683) (243,340) (191,775) (46,161) 2731 (40.85) (245,280) Interest expense, net! 240 539 sm as 1968 702 m3 656 685 2.756 Depreciation
Slide 25: Thank you
SMFR Semad Nasdaq Listed sema4